Pharmacy Benefit Management

From Specialty Pharmacy News - Although the FDA has long taken a mainly hands-off policy toward laboratory developed tests (LDTs), that is about to change. Responding to growing calls to issue draft guidance — and ignoring other pleas to maintain the status quo — the agency notified Congress on July 31 that it intends to issue such guidance within 60 days. Read more

From Specialty Pharmacy News - Although the FDA has yet to approve a product through the 351(k) biosimilar pathway, multiple follow-on drugs are working their way through the pipeline, noted Kate Keeping, senior director of biosimilars research for BioTrends Research Group at a June 30 webinar sponsored by the company. “The United States is the only developed market to have no biosimilars, but development is ramping up,” Keeping said. As of June, 23 biosimilar products were… Read more

Pharmacy Benefit Management Blog

By Lauren Flynn Kelly - September 16, 2014
Earlier this year, the category of compounded medications became a top concern for payers as PBMs like Catamaran Corp. and Express Scripts Holding Co. identified unprecedented utilization and cost increases associated with these specialized drugs in 2013. As a result, many payers have undertaken...
By Angela Maas - September 2, 2014
The FDA recently disclosed that it would issue draft guidance on regulating laboratory developed tests (LDTs). But while some stakeholders have been calling for the guidance, others are staunchly opposed to it. On July 31, the agency issued a document containing “anticipated details” of its draft...
By Lauren Flynn Kelly - August 21, 2014
Earlier this month, CVS Caremark Corp. and Express Scripts Holding Co. released updates to their 2015 formulary exclusion lists. CVS Caremark now excludes nearly 100 products from its Standard Formulary and automatically will leave out new-to-market products, including line extensions and new...

It's quick and easy to sign up for FREE access to!

Why do I need to register?